PF-04937319

 

Topic mentions per year

Topic mentions per year

2014-2016
01220142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
1. The partial glucokinase activator N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine… (More)
Is this relevant?
2017
2017
Glucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Glucokinase enhances glucose conversion to glucose-6-phosphate, causing glucose-stimulated insulin secretion from pancreatic… (More)
Is this relevant?
2015
2015
AIM To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on… (More)
Is this relevant?
2014
2014
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF… (More)
Is this relevant?
2014
2014
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?